Literature DB >> 15182236

Diminished L-arginine bioavailability in hypertension.

Monique B Moss1, Tatiana M C Brunini, Roberto Soares De Moura, Lúcia E Novaes Malagris, Norman B Roberts, J Clive Ellory, Giovanni E Mann, Antônio C Mendes Ribeiro.   

Abstract

L-Arginine is the precursor of NO (nitric oxide), a key endogenous mediator involved in endothelium-dependent vascular relaxation and platelet function. Although the concentration of intracellular L-arginine is well above the Km for NO synthesis, in many cells and pathological conditions the transport of L-arginine is essential for NO production (L-arginine paradox). The present study was designed to investigate the modulation of L-arginine/NO pathway in systemic arterial hypertension. Transport of L-arginine into RBCs (red blood cells) and platelets, NOS (NO synthase) activity and amino acid profiles in plasma were analysed in hypertensive patients and in an animal model of hypertension. Influx of L-arginine into RBCs was mediated by the cationic amino acid transport systems y+ and y+L, whereas, in platelets, influx was mediated only via system y+L. Chromatographic analyses revealed higher plasma levels of L-arginine in hypertensive patients (175+/-19 micromol/l) compared with control subjects (137+/-8 micromol/l). L-Arginine transport via system y+L, but not y+, was significantly reduced in RBCs from hypertensive patients (60+/-7 micromol.l(-1).cells(-1).h(-1); n=16) compared with controls (90+/-17 micromol.l(-1).cells(-1).h(-1); n=18). In human platelets, the Vmax for L-arginine transport via system y+L was 86+/-17 pmol.10(9) cells(-1).min(-1) in controls compared with 36+/-9 pmol.10(9) cells(-1).min(-1) in hypertensive patients (n=10; P<0.05). Basal NOS activity was decreased in platelets from hypertensive patients (0.12+/-0.02 pmol/10(8) cells; n=8) compared with controls (0.22+/-0.01 pmol/10(8) cells; n=8; P<0.05). Studies with spontaneously hypertensive rats demonstrated that transport of L-arginine via system y+L was also inhibited in RBCs. Our findings provide the first evidence that hypertension is associated with an inhibition of L-arginine transport via system y+L in both humans and animals, with reduced availability of L-arginine limiting NO synthesis in blood cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182236     DOI: 10.1042/CS20030412

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  10 in total

1.  Modeling of cellular arginine uptake by more than one transporter.

Authors:  Marietha J Nel; Angela J Woodiwiss; Geoffrey P Candy
Journal:  J Membr Biol       Date:  2011-11-24       Impact factor: 1.843

2.  The antihypertensive effect of arginine.

Authors:  Sudesh Vasdev; Vicki Gill
Journal:  Int J Angiol       Date:  2008

3.  Changes in the Plasma and Platelet Nitric Oxide Biotransformation Metabolites during Ischemic Stroke-A Dynamic Human LC/MS Metabolomic Study.

Authors:  Maciej Bladowski; Ewa Szahidewicz-Krupska; Jerzy Wiśniewski; Paulina Fortuna; Justyna Chojdak-Łukasiewicz; Slawomir Budrewicz; Mariusz Fleszar; Adrian Doroszko
Journal:  Antioxidants (Basel)       Date:  2022-05-12

4.  Uncoupled eNOS annihilates neuregulin-1β-induced cardioprotection: a novel mechanism in pharmacological postconditioning in myocardial infarction.

Authors:  Bernd Ebner; Stefan A Lange; Thomas Eckert; Clementine Wischniowski; Annette Ebner; Rüdiger C Braun-Dullaeus; Christof Weinbrenner; Carsten Wunderlich; Gregor Simonis; Ruth H Strasser
Journal:  Mol Cell Biochem       Date:  2012-10-12       Impact factor: 3.396

5.  Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk.

Authors:  W H Wilson Tang; Zeneng Wang; Leslie Cho; Danielle M Brennan; Stanley L Hazen
Journal:  J Am Coll Cardiol       Date:  2009-06-02       Impact factor: 24.094

6.  An important role for A20-binding inhibitor of nuclear factor-kB-1 (ABIN1) in inflammation-mediated endothelial dysfunction: an in vivo study in ABIN1 (D485N) mice.

Authors:  Naveed Akbar; Sambit Nanda; Jill Belch; Philip Cohen; Faisel Khan
Journal:  Arthritis Res Ther       Date:  2015-02-04       Impact factor: 5.156

7.  Essential hypertension: A filtered serum based metabolomics study.

Authors:  Keerti Ameta; Ashish Gupta; Sudeep Kumar; Rishi Sethi; Deepak Kumar; Abbas Ali Mahdi
Journal:  Sci Rep       Date:  2017-05-19       Impact factor: 4.379

8.  Combinatorial Treatment Using Umbilical Cord Perivascular Cells and Aβ Clearance Rescues Vascular Function Following Transient Hypertension in a Rat Model of Alzheimer Disease.

Authors:  Paolo Bazzigaluppi; Tina L Beckett; Margaret M Koletar; Mary E Hill; Aaron Lai; Arunachala Trivedi; Lynsie Thomason; Adrienne Dorr; Denis Gallagher; Clifford L Librach; Illsung L Joo; JoAnne McLaurin; Bojana Stefanovic
Journal:  Hypertension       Date:  2019-09-03       Impact factor: 10.190

9.  Inhibition of L-NAME-induced hypertension by combined treatment with apocynin and catalase: the role of Nox 4 expression.

Authors:  T Y Chia; V Murugaiyah; N Ak Khan; M A Sattar; M H Abdulla; E J Johns; A Ahmad; Z Hassan; G Kaur; H Y Mei; F U Ahmad; S Akhtar
Journal:  Physiol Res       Date:  2021-03-17       Impact factor: 1.881

10.  A relative L-arginine deficiency contributes to endothelial dysfunction across the stages of the menopausal transition.

Authors:  Jelena Klawitter; Kerry L Hildreth; Uwe Christians; Wendy M Kohrt; Kerrie L Moreau
Journal:  Physiol Rep       Date:  2017-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.